Yellow Fever Vaccine: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
No edit summary
Line 16: Line 16:
[[Image:Flavivirus_Life_Cycle.jpg|thumb|300px|right|Figure 4. Diagram of the Flavivirus' life cycle. Notice the initial binding to the host cell and the clathrin mediated endocytosis that follows the initial binding. Then the viral membrane fuses with the host's endosome to expose the viral ssRNA to the endoplasmic reticulum (ER). There, the ssRNA is transcribed and copied to make new viral proteins and new ssRNA. The viral particles are assembled and form a immature virion by budding off of the ER. After budding off, the immature virion moves to the Golgi. Moving from the Golgi to the host's membrane, the cell undergoes cleavages that cleave the prM protein into M proteins, maturing the virion before being secreted out of the host cell. Additionally, notice how the immature virion has a rough, spiked surface in contrast to the smooth surface of the mature virion. Diagram by Ted C. Pierson, NIH National Institute of Allergy and Infectious Diseases]]
[[Image:Flavivirus_Life_Cycle.jpg|thumb|300px|right|Figure 4. Diagram of the Flavivirus' life cycle. Notice the initial binding to the host cell and the clathrin mediated endocytosis that follows the initial binding. Then the viral membrane fuses with the host's endosome to expose the viral ssRNA to the endoplasmic reticulum (ER). There, the ssRNA is transcribed and copied to make new viral proteins and new ssRNA. The viral particles are assembled and form a immature virion by budding off of the ER. After budding off, the immature virion moves to the Golgi. Moving from the Golgi to the host's membrane, the cell undergoes cleavages that cleave the prM protein into M proteins, maturing the virion before being secreted out of the host cell. Additionally, notice how the immature virion has a rough, spiked surface in contrast to the smooth surface of the mature virion. Diagram by Ted C. Pierson, NIH National Institute of Allergy and Infectious Diseases]]


==Section 1==
==History==
<br>Include some current research, with at least one figure showing data.<br>
<br> Spaniards documented the first major occurrence of YF in Yucatan, Mexico in 1648.  Local Mayans at the time referred to the disease as xekik (black-vomit), which was a common symptom of late stage YF.  Previous to arriving in Mexico however, it is hypothesized that the disease originated in Africa and spread as a result of slave ships travelling from Africa and transporting with them infected specimens of A. aegypti in their drinking water.
 
After the Yucatan outbreak, YF spread even further around the world causing high death tolls even in Barcelona and in the Mississippi Valley.  While it is now seen as a foreign tropical disease, there were numerous outbreaks in North America up through most of the 19th century, with epidemics in New York, 4,000 deaths in New Orleans, and even at one point an outbreak in Quebec.
 
It was not until 1881 when a Cuban scientist, Dr. Carlos Finlay, proposed that YF spread through A. aegypti that people began exterminating the mosquito and subsequently almost completely eradicated YF outside of South America and Africa.  The control of the disease was best exemplified by Cuba’s Major William C. Gorgas led and implemented specific mosquito-eradication procedures which effectively eradicated YF in the area within the year in 1901.  It was thanks to extermination efforts like Gorgas’ that Panama Canal could even be built considering many workers would have otherwise succumbed to YF as they worked on the canal.
 
In 1937, Max Theiler created a live-attenuated vaccine for yellow fever by serial-passaging the YF virus through chicken embryotic tissue.  This vaccine, known as the 17D vaccine has impressively been highly effective in preventing the disease, with an unusually long antibody persistence upwards of 35 years in some individuals.  Since its production, over 500 million individuals have been vaccinated with the 17D vaccine further controlling the spread of yellow fever.  Appropriately, Max Thelier was rewarded with a Nobel Prize in 1951 for his contributions.

Revision as of 05:21, 22 April 2014

Overview

Figure 1. Photo of a female Aedes Aegypti, the most common vector of the Yellow Fever Virus. Photo taken by James Gathany for the CDC's Public Health Image Library


By Christopher Kei Helm


Yellow fever is a human disease caused by the yellow fever virus, prevalent mostly in tropical climates. The yellow fever virus is a part of a family of viruses known as the Flavivirdae and the genus Flavivirus that fall under a broader category of arboviruses, or “arthropod-borne” viruses. In this case, most common arthropod vector of YF is the Aedes aegypti mosquito.

As stated previously, the disease is usually only prevalent in tropical regions of the world, mostly South America and parts of Africa (see figure 2). Even with vaccines available, yellow fever (YF) still causes 30,000 deaths annually with almost 200,000 cases occurring in Africa. Moreover, YF is an acute infection, with mortality rates ranging from 25~50%. Even worse, the number of cases of YF has increased in the past 20 years as a result of declining immunity among susceptible populations to infection, climate change, and urbanization. Because of this, YF is a critical public health issue in South America and Africa.


Figure 2. Map depicting geographic high risk areas for Yellow Fever, published by the WHO, July 2013.


Figure 3. Diagram of a Flaviviridae virion. Note the three types of proteins composing the virion's membrane (E, M, C). Also notice the herringbone-like arrangements the E proteins form on the right hand diagram. Figure is the property of the SIB Swiss Institute of Bioinformatics


Figure 4. Diagram of the Flavivirus' life cycle. Notice the initial binding to the host cell and the clathrin mediated endocytosis that follows the initial binding. Then the viral membrane fuses with the host's endosome to expose the viral ssRNA to the endoplasmic reticulum (ER). There, the ssRNA is transcribed and copied to make new viral proteins and new ssRNA. The viral particles are assembled and form a immature virion by budding off of the ER. After budding off, the immature virion moves to the Golgi. Moving from the Golgi to the host's membrane, the cell undergoes cleavages that cleave the prM protein into M proteins, maturing the virion before being secreted out of the host cell. Additionally, notice how the immature virion has a rough, spiked surface in contrast to the smooth surface of the mature virion. Diagram by Ted C. Pierson, NIH National Institute of Allergy and Infectious Diseases

History


Spaniards documented the first major occurrence of YF in Yucatan, Mexico in 1648. Local Mayans at the time referred to the disease as xekik (black-vomit), which was a common symptom of late stage YF. Previous to arriving in Mexico however, it is hypothesized that the disease originated in Africa and spread as a result of slave ships travelling from Africa and transporting with them infected specimens of A. aegypti in their drinking water.

After the Yucatan outbreak, YF spread even further around the world causing high death tolls even in Barcelona and in the Mississippi Valley. While it is now seen as a foreign tropical disease, there were numerous outbreaks in North America up through most of the 19th century, with epidemics in New York, 4,000 deaths in New Orleans, and even at one point an outbreak in Quebec.

It was not until 1881 when a Cuban scientist, Dr. Carlos Finlay, proposed that YF spread through A. aegypti that people began exterminating the mosquito and subsequently almost completely eradicated YF outside of South America and Africa. The control of the disease was best exemplified by Cuba’s Major William C. Gorgas led and implemented specific mosquito-eradication procedures which effectively eradicated YF in the area within the year in 1901. It was thanks to extermination efforts like Gorgas’ that Panama Canal could even be built considering many workers would have otherwise succumbed to YF as they worked on the canal.

In 1937, Max Theiler created a live-attenuated vaccine for yellow fever by serial-passaging the YF virus through chicken embryotic tissue. This vaccine, known as the 17D vaccine has impressively been highly effective in preventing the disease, with an unusually long antibody persistence upwards of 35 years in some individuals. Since its production, over 500 million individuals have been vaccinated with the 17D vaccine further controlling the spread of yellow fever. Appropriately, Max Thelier was rewarded with a Nobel Prize in 1951 for his contributions.